

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Endocrine/metabolic disease</b>				
Diabetes	CD3; insulin (INS; proinsulin); IL-10	<p>Studies in mice suggest <i>Lactococcus lactis</i> engineered to secrete both IL-10 and proinsulin could help treat type 1 diabetes. In diabetic mice, oral dosing of IL-10- and proinsulin-secreting <i>L. lactis</i> plus a low-dose systemic anti-CD3 mAb reversed autoimmune diabetes in 59% of the animals, whereas it was only reversed in 25% of mice given the antibody alone. Mice receiving the combination therapy also had lower insulinitis and better preservation of functional <math>\beta</math> cell mass than animals given anti-CD3 mAb alone. Next steps include toxicology studies.</p> <p>ActoGeniX N.V.'s AG013, an oral rinsing solution containing <i>L. lactis</i> engineered to secrete trefoil factor 1 (TFF1), is in Phase I testing to prevent oral mucositis.</p> <p><b>SciBX 5(19); doi:10.1038/scibx.2012.493</b>  <b>Published online May 10, 2012</b></p>	Patented by ActoGeniX; available for licensing	<p>Takiishi, T. <i>et al. J. Clin. Invest.</i>; published online April 9, 2012; doi:10.1172/JCI60530</p> <p><b>Contact:</b> Chantal Mathieu, Catholic University Leuven, Leuven, Belgium            e-mail: <a href="mailto:chantal.mathieu@uzleuven.be">chantal.mathieu@uzleuven.be</a></p>